A retired physician allegedly wrote dozens of prescriptions without ever seeing the patients, according to the Drug Enforcement Administration.
Federal and local investigators charged a New York physician and his son with selling prescriptions for opioids, stimulants, and benzodiazepines outside the course of medical practice and without a legitimate medical purpose. According to authorities, the physician issued prescriptions based solely on names and drug requests between April and June 2022, relayed by his son, without conducting medical evaluations. The prescriptions—oxycodone-acetaminophen, dextroamphetamine-amphetamine, and alprazolam—were sent electronically to pharmacies, with some drugs later resold or traded for cash or drugs. Pharmacists first flagged the pattern, prompting a multi-year investigation that ultimately led to charges, including criminal sale of prescriptions for controlled substances and conspiracy.
The underappreciated moment isn't the volume of prescriptions, but the mechanism: a physician operating outside standard patient evaluation, carried out through electronic prescribing systems with limited real-time oversight, and a bypass of the clinical encounter itself.
The friction sits in the gray zone between trust and verification. Because electronic prescribing systems are built for efficiency, not scrutiny, pharmacists only recognized irregularities after patterns emerged. Regulators intervened, but only after months of activity. What stands out here is how much the system depends on professional integrity yet offers limited real-time safeguards when that integrity fails.
The case suggests that oversight may lag behind prescribing power. Health systems and regulators may need to rethink how prescribing authority is monitored in real time—not just audited after harm is suspected.
“Medical professionals are entrusted with protecting patients’ lives, not destroying them by exploiting them to addiction and harm,” said Farhana Islam, Drug Enforcement Administration (DEA) New York Enforcement Division Special Agent in Charge.
Source: DEA
